Nutriband Inc. (NASDAQ: NTRB), a company developing transdermal pharmaceutical products, announced the appointment of Robert J. O’Neill to its Advisory Board. O’Neill served 16 years in the U.S. Navy, including eight years with the Naval Special Warfare Development Group (SEAL Team Six), and participated in more than 400 combat missions. He is also a New York Times best-selling author and advocate for expanding veterans’ access to emerging health treatments.
O’Neill will support Nutriband’s executive team on strategy, growth and execution as the company advances its pipeline of abuse-deterrent transdermal products, including AVERSA Fentanyl. The company said AVERSA Fentanyl would be the world’s first and only abuse-deterrent fentanyl patch if approved. This appointment matters because it brings high-profile leadership and strategic guidance to a company at a critical stage of developing a product that could address the ongoing opioid crisis by reducing the potential for abuse, misuse, diversion and accidental exposure of fentanyl patches.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company’s website is www.nutriband.com.
O’Neill’s military background and advocacy for veterans’ health align with Nutriband’s mission to develop safer pharmaceutical options. His experience leading complex missions and his public profile could help the company navigate regulatory and commercial challenges as it seeks approval for AVERSA Fentanyl. The appointment also signals to investors that Nutriband is strengthening its advisory capabilities ahead of potential milestones.
The full press release is available at https://ibn.fm/WuoNR. The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB.
InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
